Endo International (NASDAQ:ENDP) (TSE:ENL) had its price target dropped by investment analysts at Cantor Fitzgerald from $18.00 to $4.75 in a research note issued to investors on Wednesday, The Fly reports. The firm presently has a “neutral” rating on the stock. Cantor Fitzgerald’s target price would indicate a potential upside of 6.26% from the company’s previous close.
A number of other research analysts have also weighed in on the company. Zacks Investment Research lowered Endo International from a “hold” rating to a “sell” rating in a report on Wednesday, February 13th. Piper Jaffray Companies reissued a “hold” rating on shares of Endo International in a report on Friday, March 1st. Leerink Swann lowered Endo International from an “outperform” rating to a “market perform” rating in a report on Tuesday, March 5th. Svb Leerink lowered Endo International from an “outperform” rating to a “market perform” rating in a report on Tuesday, March 5th. Finally, ValuEngine lowered Endo International from a “hold” rating to a “sell” rating in a report on Wednesday, March 6th. Three equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating and six have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $13.57.
Endo International stock opened at $4.47 on Wednesday. Endo International has a one year low of $4.18 and a one year high of $18.50. The stock has a market capitalization of $1.01 billion, a price-to-earnings ratio of 1.62 and a beta of 1.35.
Institutional investors and hedge funds have recently modified their holdings of the business. LS Investment Advisors LLC acquired a new stake in Endo International in the fourth quarter valued at approximately $59,000. Oregon Public Employees Retirement Fund acquired a new stake in Endo International in the fourth quarter valued at approximately $76,000. Signition LP acquired a new stake in Endo International in the first quarter valued at approximately $139,000. Neuburgh Advisers LLC grew its holdings in Endo International by 13.9% in the fourth quarter. Neuburgh Advisers LLC now owns 24,860 shares of the company’s stock valued at $181,000 after purchasing an additional 3,036 shares during the period. Finally, Factorial Partners LLC acquired a new stake in Endo International in the first quarter valued at approximately $193,000. 93.59% of the stock is currently owned by institutional investors.
About Endo International
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
See Also: Trading based on a resistance level
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.